Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Mohamed Hebbar

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6304-8592; OpenAlex author ID A5083239485. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
27
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 8

  1. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  2. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  3. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1809775↗
  4. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: A retrospective analysis. Last author DOI 10.1016/j.pan.2016.12.009↗
  5. Locally Advanced or Metastatic Pancreatic Adenocarcinoma: Easily Available Factors of Predictive Prolonged Survival Under Gemcitabine. Last author DOI 10.21873/invivo.11122↗
  6. Deep Vein Thrombosis: An Independent Poor Prognosis Factor of Advanced Pancreatic Adenocarcinoma. Last author DOI 10.21873/anticanres.11135↗
  7. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mdv133↗
  8. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. Co-author DOI 10.1038/onc.2012.179↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anne Ploquin · 3 shared papers, 2016–2017 · strength 0.21
  2. Capucine Baldini · 2 shared papers, 2017 · strength 0.14
  3. Stéphanie Truant · 2 shared papers, 2016–2017 · strength 0.14
  4. Pascal R. Hammel · 2 shared papers, 2015–2018 · strength 0.10
  5. Olivier Bouché · 1 shared paper, 2017 · strength 0.07
  6. Anthony Turpin · 1 shared paper, 2016 · strength 0.06
  7. M. Lambert · 1 shared paper, 2016 · strength 0.06
  8. Patrick Rat · 1 shared paper, 2018 · strength 0.05
  9. Frédéric Di Fiore · 1 shared paper, 2018 · strength 0.05
  10. Marc Ychou · 1 shared paper, 2018 · strength 0.05
  11. Thierry Conroy · 1 shared paper, 2018 · strength 0.05
  12. James Biagi · 1 shared paper, 2018 · strength 0.05
  13. Petr Kavan · 1 shared paper, 2018 · strength 0.05
  14. Alain Sauvanet Sauvanet · 1 shared paper, 2018 · strength 0.05
  15. David Malka · 1 shared paper, 2018 · strength 0.05
  16. Eric Assénat · 1 shared paper, 2018 · strength 0.05
  17. Roger Faroux · 1 shared paper, 2018 · strength 0.05
  18. Jean‐Baptiste Bachet · 1 shared paper, 2018 · strength 0.05
  19. Jean‐Luc Raoul · 1 shared paper, 2018 · strength 0.05
  20. Alice Chia-Chi Wei · 1 shared paper, 2018 · strength 0.05
  21. Éric François · 1 shared paper, 2018 · strength 0.05
  22. Nicolas Skrypek · 1 shared paper, 2013 · strength 0.04
  23. Isabelle VAN SEUNINGEN · 1 shared paper, 2013 · strength 0.04
  24. Nicolas Jonckheere · 1 shared paper, 2013 · strength 0.04
  25. G. Deplanque · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.